02 January 2022>: Clinical Research
Retrospective Study of 573 Patients with Heart Failure Evaluated for Coronary Artery Disease at Toulouse University Center, France
Antoine Deney 1ABCDEF* , Vanessa Nader 12ABCDEF* , Anthony Matta 13ABCDE , Romain Itier 1CDE , Pauline Fournier 1ABCD , Olivier Lairez 1ADF , Nathalie Pizzinat 4ACD , Didier Carrié 1ACD , Frédéric Boal 4ACD , Michel Galinier 1ACD , Oksana Kunduzova 4ACD , Rania Azar 2ACD , Jerome Roncalli 14ABCDEFG*DOI: 10.12659/MSM.934804
Med Sci Monit 2022; 28:e934804
Table 5 Characteristics of the study population stratified by the presence of coronary artery disease.
Studied populationN=573 | No-CADN=253 | Significant CADN=320 | P-value | |
---|---|---|---|---|
Age | 68.28±12.25 | 64.90±13.532 | 70.95±10.404 | |
Male sex | 438 (76.44%) | 169 (66.80%) | 269 (84.06%) | 0.171 |
BMI | 27.89±18.104 | 29.92±26.581 | 26.28±4.864 | 0.033 |
Atrial fibrillation | 174 (30.37%) | 79 (31.23%) | 95 (29.69%) | 0.691 |
HFrEF | 484 (84.47%) | 214 (84.58%) | 270 (84.37%) | 0.945 |
Chronic kidney disease | 266 (46.42%) | 84 (33.20%) | 182 (56.87%) | |
Dyslipidemia | 164 (28.62%) | 58 (22.92%) | 106 (33.13%) | 0.041 |
Diabetes | 171 (29.84%) | 58 (22.92%) | 113 (35.31%) | 0.010 |
Hypertension | 309 (53.93%) | 111 (43.87%) | 198 (61.87%) | 0.001 |
Smoking | 144 (25.13%) | 59 (23.32%) | 85 (26.56%) | 0.802 |
Family history | 89 (15.53%) | 42 (16.60%) | 47 (14.69%) | 0.261 |
Valvulopathy | 224 (39.09%) | 93 (36.76%) | 131 (40.93%) | 0.284 |
RVD | 110 (19.20%) | 52 (20.55%) | 58 (18.13%) | 0.535 |
TAPSE | 16.77±4.45 | 16.05±4.35 | 17.29±4.48 | 0.026 |
PAPSE | 41.38±13.30 | 16.05±4.347 | 17.29±4.472 | 0.026 |
Pacemaker | 41 (7.16%) | 15 (5.93%) | 26 (8.13%) | 0.307 |
Defibrillator | 38 (6.63%) | 12 (4.74%) | 26 (8.13%) | 0.106 |
NYHA class | ||||
1 | 23 (4.01%) | 10 (3.95%) | 14 (4.38%) | 0.964 |
2 | 143 (24.96%) | 60 (23.72%) | 83 (25.94%) | |
3 | 149 (26%) | 62 (24.51%) | 87 (27.19%) | |
4 | 47 (8.20%) | 22 (8.70%) | 25 (7.81%) | |
Systolic blood pressure | 128.86±22.80 | 127.64±22.37 | 129.77±23.12 | 0.325 |
Diastolic blood pressure | 75.27±15.84 | 76.30±17.90 | 74.50±14.09 | 0.233 |
Heart rate | 82.07±20.79 | 85.79±20.26 | 79.25±20.78 | 0.001 |
Troponin | 143.87±543.08 | 100.90±280.22 | 1169.84±652.32 | 0.368 |
NT-ProBNP | 5535.15±8523.84 | 5232.62±8247.12 | 5789.47±8758.01 | 0.485 |
β-blockers | 324 (56.54%) | 130 (51.38%) | 194 (60.63%) | 0.027 |
Diuretics | 328 (57.24%) | 137 (54.15%) | 191 (59.69%) | 0.169 |
Mineralocorticoids | 95 (16.58%) | 40 (15.81%) | 84 (17.19%) | 0.663 |
ACE/ARA | 289 (50.44%) | 114 (45.06%) | 175 (54.69%) | 0.025 |
ARNI | 45 (7.85%) | 21 (8.30%) | 24 (7.50%) | 0.724 |
Ivabradine | 7 (1.22%) | 2 (0.79%) | 5 (1.56%) | 0.472 |
SAPT | 172 (30.02%) | 44 (17.39%) | 128 (40.00%) | |
DAPT | 47 (8.20%) | 4 (1.58%) | 43 (13.44%) | |
DOAC+AVK | 164 (28.62%) | 70 (27.67%) | 94 (29.37%) | 0.637 |
AAP+OAC | 35 (6.11%) | 5 (1.977%) | 30 (9.38%) | 0.05 |
β-blockers | 480 (83.77%) | 213 (84.19%) | 267 (83.44%) | 0.851 |
Diuretics | 439 (76.61%) | 194 (76.68%) | 245 (76.56%) | 0.810 |
Mineralocorticoids | 231 (40.31%) | 114 (45.06%) | 117 (36.56%) | 0.048 |
ACE/ARA | 332 (57.94%) | 150 (59.29%) | 182 (56.88%) | 0.643 |
ARNI | 137 (23.90%) | 71 (28.06%) | 66 (20.62%) | 0.041 |
Ivabradine | 19 (3.32%) | 8 (3.16%) | 11 (3.44%) | 0.833 |
SAPT | 120 (20.94%) | 41 (16.20%) | 79 (24.68%) | 0.011 |
DAPT | 215 (37.52%) | 14 (5.53%) | 201 (62.81%) | |
DOAC+AVK | 217 (37.87%) | 106 (41.89%) | 111 (34.69%) | 0.480 |
AAP+OAC | 82 (14.31%) | 5 (1.98%) | 77 (24.06%) |